Androgens in postmenopausal women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The use of androgens in postmenopausal women is now being actively discussed. The review gives the latest data on hormonal profile changes in postmenopausal women, describes factors influencing the circulation of androgens, and evaluates the effect of low-dose androgens on the sexual function of postmenopausal women. It also presents clinical trials dealing with androgen therapy and discusses the potential risks of this therapy in the treatment of sexual dysfunction in postmenopausal women.

Full Text

Restricted Access

About the authors

V. E Balan

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: balanmed@gmail.com
prof., head of the Polyclinic Department

Ya. Z Zaidieva

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: 7726l0l@rambler.ru
prof., head of the Department of Gynecological Endocrinology

A. V Tsarkova

Moscow Regional Research Institute of Obstetrics and Gynecology

Email: alinka-lapina@mail.ru
doctor of the Polyclinic Department

References

  1. Butenandt A. The chemical investigation of the sex hormone. Z. Angew. Chem. 1931; 44: 905-8.
  2. David K., Dingemanse E., Freud J., Laqueur E. Uber krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron. Hoppe Seylers Z. Physiol. Chem. 1935 233: 281.
  3. Davis S., Panjari M., Stanczyk F. Clinical review: DHEA replacement for postmenopausal women. J. Clin. Endocrinol. Metab. 2011; 96(6): 1642-53.
  4. Pretorius E., Africander D.J., Vlok M., Perkins M.S., Quanson J., Storbeck K.H. 11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. PLoS One. 2016; 11(7): e0159867.
  5. Pretorius E., Arlt W., Storbeck K.H. A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids. Mol. Cell. Endocrinol. 2016; 44: 76-85.
  6. Haring R., Hannemann A., John U., Radke D., Nauck M., Wallaschofski H. et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J. Clin. Endocrinol. Metab. 2012; 97(2): 408-15.
  7. van der Stege J.G., Groen H., van Zadelhoff S.J., Lambalk C.B., Braat D.D., van Kasteren Y.M. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008; 15(1): 23-31.
  8. Pugeat M., Nader N., Hogeveen K., Raverot G., Dechaud H., Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol. Cell. Endocrinol. 2010; 316: 53-9.
  9. Wahlin-Jacobsen S., Pedersen A.T., Kristensen E., Laessoe N.C., Lundqvist M., Cohen A.S. et al. Is there a correlation between androgens and sexual desire in women? J. Sex. Med. 2015; 12(2): 358-73.
  10. Randolph J.F. Jr., Zheng H., Avis N.E., Greendale G.A., Harlow S.D. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J. Clin. Endocrinol. Metab. 2015; 100(1): 258-66.
  11. Wierman M.E., Arlt W., Basson R., Davis S.R., Miller K.K., Murad M.H. et al. Androgen therapy in women: a reappraisal: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2014; 99(10): 3489-510.
  12. Huang G., Basaria S., Travison T.G., Ho M.H., Davda M., Mazer N.A. et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014; 21(6): 612-23.
  13. Spoletini I., Vitale C., Pelliccia F., Fossati C., Rosano G.M. Androgens and cardiovascular disease in postmenopausal women: a systematic review. Climacteric. 2014; 17(6): 625-34.
  14. Davis S.R., Wahlin-Jacobsen S. Testosterone in women: the clinical significance. Lancet Diabetes Endocrinol. 2015; 3(12): 980-92.
  15. Benn M., Voss S.S., Holmegard H.N., Jensen G.B., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women. Arterioscler. Thromb. Vasc. Biol. 2015; 35(2): 471-7.
  16. Naessen T., Sjogren U., Bergquist J., Larsson M., Lind L., Kushnir M.M. Endogenous steroids measured by high-specificity liquid chromatographytandem mass spectrometry and prevalent cardiovascular disease in 70-yearold men and women. J. Clin. Endocrinol. Metab. 2010; 95(4): 1889-97.
  17. Davis S.R., Robinson P.J., Moufarege A., Bell R.J. The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women. Clin. Endocrinol. (Oxford). 2012; 77(4): 541-7.
  18. Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., Rifai N. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 2009; 361(12): 1152-63.
  19. Pike C.J., Carroll J.C., Rosario E.R., Barron A.M. Protective actions of sex steroid hormones in Alzheimer’s disease. Front. Neuroendocrinol. 2009; 30(2): 239-58.
  20. Davis S.R., Davison S.L., Gavrilescu M., Searle K., Gogos A., Rossell S.L. et al. Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women: results from a functional magnetic resonance imaging pilot study. Menopause. 2014; 21(4): 410-4.
  21. Davison S.L., Bell R.J., Gavrilescu M., Searle K., Maruff P., Gogos A. et al. Testosterone improves verbal learning and memory in postmenopausal women: results from a pilot study. Maturitas. 2011; 70(3): 307-11.
  22. Clarke B.L., Khosla S. Androgens and bone. Steroids. 2009; 74(3): 296-305.
  23. Rariy C.M., Ratcliffe S.J., Weinstein R., Bhasin S., Blackman M.R., Cauley J.A. et al. Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study. J. Clin. Endocrinol. Metab. 2011; 96(4): 989-96.
  24. Finigan J., Gossiel F., Gluer C.C., Felsenberg D., Reid D.M., Roux C., Eastell R. Endogenous estradiol and the risk of incident fracture in postmenopausal women: the OPUS study. Calcif. Tissue Int. 2012; 91(1): 59-68.
  25. Davis S.R., Moreau M., Kroll R., Bouchard C., Panay N., Gass M. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 2008; 359(19): 2005-17.
  26. Huang G., Basaria S., Travison T.G., Ho M.H., Davda M., Mazer N.A. et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014; 21(6): 612-23.
  27. Alkatib A.A., Cosma M., Elamin M.B., Erickson D., Swiglo B.A., Erwin P.J., Montori V.M. A systematic review and metaanalysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J. Clin. Endocrinol. Metab. 2009; 94(10): 3676-81.
  28. Elraiyah T., Sonbol M.B., Wang Z., Khairalseed T., Asi N., Undavalli C. et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2014; 99(10): 3536-42.
  29. La brie F, Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23(3): 243-56.
  30. Baldassarre M., Perrone A.M., Giannone F.A., Armillotta F., Battaglia C., Costantino A. et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int. J. Impot. Res. 2013; 25(1): 7-11.
  31. Fernandes T., Costa-Paiva L.H., Pedro A.O., Baccaro L.F., Pinto-Neto A.M. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial. Menopause. 2016; 23(7): 792-8.
  32. Witherby S., Johnson J., Demers L., Mount S., Littenberg B., Maclean C.D. et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist. 2011; 16(4): 424-31.
  33. Wierman M.E., Arlt W., Basson R., Davis S.R., Miller K.K., Murad M.H. et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014; 99(10): 3489-510.
  34. Huang G., Pencina K.M., Coady J.A., Beleva Y.M., Bhasin S., Basaria S. Functional voice testing detects early changes in vocal pitch in women during testosterone administration. J. Clin. Endocrinol. Metab. 2015; 100(6): 2254-60.
  35. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68.
  36. Fooladi E., Reuter S.E., Bell R.J., Robinson P.J., Davis S.R. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause. 2015; 22: 44-9.
  37. Ali A., Berens P., Siddiqui G., Ali V. Nipple and areolar hyperpigmentation secondary to the use of estradiol spray on the ipsilateral forearm skin: a report of two cases. J. Womens Health (Larchmt). 2012; 21(3): 363-5.
  38. Elraiyah T., Sonbol M.B., Wang Z., Khairalseed T., Asi N., Undavalli C. et al. Cli nical review:The benefits and harms of systemic testosterone therapy in postme nopausalwomen with normal adrenal function: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 2014; 99(10): 3543-50.
  39. Davis S., Papalia M., Norman R., O’Neill S., Redelman M., Williamson M. et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women. Ann. Intern. Med. 2008; 148(8): 569-77.
  40. Goldstat R., Briganti E., Tran J., Wolfe R., Davis S. Transdermal testosterone therapy improves well-being, mood and sexual function in premenopausal women. Menopause. 2009; 10(5): 390-8.
  41. Zeleke B.M., Bell R.J., Billah B., Davis S.R. Hypoactive sexual desire dysfunction in community-dwelling older women. Menopause. 2017; 24(4): 391-9.
  42. Shifren J.L., Davis S.R. Androgens in postmenopausal women. Menopause. 2017; 24(8): 970-9.
  43. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (протокол лечения). М.; 2015. 54с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies